Q&A on access to HIV prevention drug CAB-LA

The access barriers on lifesaving TB tools

Ongoing PPR processes offer a promising pathway to complement and help implement pre-existing commitments on AMR

MSF’s analysis of the proposed negotiating text of the WHO pandemic accord

Despite being curable, why is TB the world’s deadliest infectious disease? What tools do we have to beat the disease?

The ongoing PPR negotiations at WHO offer an opportunity to resolve the decades-long tension between IP and access

Q&A on “Time for $5”, a campaign for affordable diagnostic tests

The “Time for $5” campaign calls on Cepheid and its parent corporation, Danaher, to prioritise people over profits and reduce the price of GeneXpert tests to $5

Principles and actions for equitable access to medical products

Despite their contributions to the R&D of new Ebola treatments, patients, treatment providers and endemic countries do not have reliable access

The second in a series of roundtables focused on clinical trial cost transparency

Global access to point-of-care CD4 devices and tests is under threat

MSF’s recommendations on the WHO Pandemic Prevention, Preparedness and Response Accord zero draft

Access to long-acting medicines will be key to meeting global HIV prevention and treatment targets.

This policy is a commitment to publishing research protocols, registering clinical trials on appropriate registries, and subsequently publishing clinical trial data in open access formats, in line with the WHO’s joint statement on ...

TB was the leading cause of death from a single infectious agent until the COVID pandemic. The number of people newly diagnosed with TB in 2020 fell by 18% from the previous year due to disruptions to health systems and services caused ...

The UK has tabled harmful provisions that threaten to tighten the screws on producing, supplying and exporting affordable generic medicines from India

Clinical trial cost transparency can inform evidence-based policy making and enable governments and treatment providers to regulate and negotiate prices more effectively.

The challenges and opportunities offered by increasing local production of diagnostic tests in the African region

The patent opposition mechanism is a critical public health safeguard under the Indian Patents Act